AU2017340245B2 - Compositions comprising PEDF-derived short peptides and uses thereof - Google Patents

Compositions comprising PEDF-derived short peptides and uses thereof Download PDF

Info

Publication number
AU2017340245B2
AU2017340245B2 AU2017340245A AU2017340245A AU2017340245B2 AU 2017340245 B2 AU2017340245 B2 AU 2017340245B2 AU 2017340245 A AU2017340245 A AU 2017340245A AU 2017340245 A AU2017340245 A AU 2017340245A AU 2017340245 B2 AU2017340245 B2 AU 2017340245B2
Authority
AU
Australia
Prior art keywords
xaa
misc
feature
amino acid
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017340245A
Other languages
English (en)
Other versions
AU2017340245A1 (en
Inventor
Tsung-Chuan Ho
Frank Wen-Chi LEE
Kuanyin Karen LIN
Yeou-Ping Tsao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brim Biotechnology Inc
Original Assignee
Brim Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brim Biotechnology Inc filed Critical Brim Biotechnology Inc
Publication of AU2017340245A1 publication Critical patent/AU2017340245A1/en
Priority to AU2022204557A priority Critical patent/AU2022204557A1/en
Application granted granted Critical
Publication of AU2017340245B2 publication Critical patent/AU2017340245B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2017340245A 2016-10-07 2017-08-24 Compositions comprising PEDF-derived short peptides and uses thereof Active AU2017340245B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022204557A AU2022204557A1 (en) 2016-10-07 2022-06-28 Compositions comprising pedf-derived short peptides and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405522P 2016-10-07 2016-10-07
US62/405,522 2016-10-07
PCT/US2017/048340 WO2018067244A1 (en) 2016-10-07 2017-08-24 Compositions comprising pedf-derived short peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022204557A Division AU2022204557A1 (en) 2016-10-07 2022-06-28 Compositions comprising pedf-derived short peptides and uses thereof

Publications (2)

Publication Number Publication Date
AU2017340245A1 AU2017340245A1 (en) 2019-05-23
AU2017340245B2 true AU2017340245B2 (en) 2022-07-21

Family

ID=61831898

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017340245A Active AU2017340245B2 (en) 2016-10-07 2017-08-24 Compositions comprising PEDF-derived short peptides and uses thereof
AU2022204557A Abandoned AU2022204557A1 (en) 2016-10-07 2022-06-28 Compositions comprising pedf-derived short peptides and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022204557A Abandoned AU2022204557A1 (en) 2016-10-07 2022-06-28 Compositions comprising pedf-derived short peptides and uses thereof

Country Status (10)

Country Link
US (1) US11760784B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596104A4 (cg-RX-API-DMAC7.html)
JP (2) JP7573967B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230169375A (cg-RX-API-DMAC7.html)
CN (1) CN110312732A (cg-RX-API-DMAC7.html)
AU (2) AU2017340245B2 (cg-RX-API-DMAC7.html)
EA (1) EA037698B1 (cg-RX-API-DMAC7.html)
IL (1) IL265796B2 (cg-RX-API-DMAC7.html)
TW (1) TWI878203B (cg-RX-API-DMAC7.html)
WO (2) WO2018067244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210221862A1 (en) * 2018-04-08 2021-07-22 Brim Biotechnology, Inc. Application of pedf-derived short peptides in the treatment of osteoarthritis
EP3761959A4 (en) * 2018-04-08 2022-03-02 Brim Biotechnology, Inc. APPLICATION OF PEDF DERIVED SHORT PEPTIDES IN TENDON HEALING
KR20210005696A (ko) * 2018-05-04 2021-01-14 브림 바이오테크놀로지, 인코퍼레이티드 마이봄 샘 재생을 촉진하기 위한 pedf-유래 펩타이드 및 그것의 사용
CN111632128B (zh) * 2019-02-14 2022-07-05 三凡生技研发股份有限公司 短链胜肽组合物在预防或治疗干眼症的应用
TWI759610B (zh) * 2019-06-27 2022-04-01 晶碩光學股份有限公司 具有角膜修護功能的眼用產品
EP4021917A4 (en) * 2019-08-27 2023-05-24 Yeou-Ping Tsao SHORT SYNTHETIC PEPTIDES AND THEIR USES FOR TREATING DEGENERATIVE RETINA DISEASES AND/OR TISSUE DAMAGE
TWI744683B (zh) * 2019-08-27 2021-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途
JP2022550907A (ja) * 2019-10-06 2022-12-05 ブリム バイオテクノロジー インク Ｐｅｄｆ由来短ペプチド（ｐｄｓｐ）を含む組成物及びその使用
CN112206312A (zh) * 2020-11-19 2021-01-12 北京大学第三医院（北京大学第三临床医学院） 一种包含pedf的用于治疗干眼的药物组合物
CN115364199A (zh) * 2021-05-19 2022-11-22 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途
KR20250023387A (ko) * 2022-06-13 2025-02-18 브림 바이오테크놀로지, 인코퍼레이티드 안구 건조증 질환 치료를 위한 pedf 유래 짧은 펩타이드를 포함하는 조성물
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260180A1 (en) * 2004-03-12 2005-11-24 Genvec, Inc. Materials and methods for treating vascular leakage in the eye
WO2007095350A2 (en) * 2006-02-15 2007-08-23 Yale University Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
WO2011044216A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
EP2508196A1 (en) * 2011-03-23 2012-10-10 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing
US20150079094A1 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional Peptide Analogs of PEDF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
EP1684692A2 (en) * 2003-10-29 2006-08-02 The Johns Hopkins University Pigment epithelium-derived factor, novel biological activity and methods of use
EP2716763A3 (en) * 2008-04-29 2014-07-02 Monsanto Technology LLC Genes and uses for plant enhancement
TWI554521B (zh) * 2011-10-19 2016-10-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
EP3339317A1 (en) * 2012-08-09 2018-06-27 MacKay Memorial Hospital Use of pedf-derived polypeptides for promoting muscle regeneration
US9815878B2 (en) * 2012-09-19 2017-11-14 Mackay Memorial Hospital Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging
AU2012390210B2 (en) * 2012-09-20 2017-06-29 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating osteoarthritis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260180A1 (en) * 2004-03-12 2005-11-24 Genvec, Inc. Materials and methods for treating vascular leakage in the eye
WO2007095350A2 (en) * 2006-02-15 2007-08-23 Yale University Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
WO2011044216A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
EP2508196A1 (en) * 2011-03-23 2012-10-10 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing
US20150079094A1 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional Peptide Analogs of PEDF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jiucheng He et al. Investigative Ophthalmology & Visual Science, 2015, 56(6), 3505 *
Tsung-Chuan Ho et al. Stem Cells, 2013, 31(9), 1775-1784 *

Also Published As

Publication number Publication date
JP2022185042A (ja) 2022-12-13
AU2022204557A1 (en) 2022-07-21
WO2018067244A1 (en) 2018-04-12
EP3596104A4 (en) 2021-02-17
TW201822785A (zh) 2018-07-01
AU2017340245A1 (en) 2019-05-23
KR20230169375A (ko) 2023-12-15
EP3596104A1 (en) 2020-01-22
WO2018067217A2 (en) 2018-04-12
CN110312732A (zh) 2019-10-08
IL265796B1 (en) 2024-10-01
IL265796B2 (en) 2025-02-01
EA201990885A1 (ru) 2019-08-30
US11760784B2 (en) 2023-09-19
TWI878203B (zh) 2025-04-01
WO2018067217A3 (en) 2019-05-02
KR20190066030A (ko) 2019-06-12
JP7573967B2 (ja) 2024-10-28
EA037698B1 (ru) 2021-05-12
US20190248859A1 (en) 2019-08-15
JP2019533722A (ja) 2019-11-21
IL265796A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
AU2017340245B2 (en) Compositions comprising PEDF-derived short peptides and uses thereof
Upadhyay et al. Oxidative stress in the retina and retinal pigment epithelium (RPE): Role of aging, and DJ-1
JP7374953B2 (ja) 眼の感染症および疾患を処置するための組成物および方法
Yang et al. 0.005% preservative-free latanoprost induces dry eye-like ocular surface damage via promotion of inflammation in mice
US20100273748A1 (en) Antimicrobial therapy
US20240123032A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
Lin et al. Serine protease inhibitor A3K suppressed the formation of ocular surface squamous metaplasia in a mouse model of experimental dry eye
Chen et al. Aim2 deficiency ameliorates lacrimal gland destruction and corneal epithelium defects in an experimental dry eye model
Junqueira et al. Experimental candidosis and recovery of Candida albicans from the oral cavity of ovariectomized rats
AU2019262664B2 (en) PEDF-derived peptides for promoting meibomian gland regeneration and uses thereof
Argenti The role of mitochondrial dysfunction in Huntington's disease: pathogenesis and its relation with striatal Rhes protein
US6656461B1 (en) Therapeutic treatment of chronic obstructive pulmonary disease
KR101567921B1 (ko) Ｏｔｘ２ 단백질을 유효성분으로 포함하는 미토콘드리아 이상질환 예방 및 치료용 조성물
Liu et al. Mitochondrial-Derived Peptide MOTS-c Targets SLC7A11 to Preserve Spermatogenesis by Suppressing Ferroptosis
WO2017049001A1 (en) Protection and sealing of the ocular surface barrier by clusterin
Ratay Controlled Release of an HDAC Inhibitor for Reduction of Inflammation in Dry Eye Disease Michelle L. Ratay, Stephen C. Balmert, Ethan J. Bassin c, and Steven R. Little

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)